Reutericyclin

Reutericyclin is a selective anti-Gram-positive substance with good oral bioavailability, possessing both antibacterial and anti-obesity effects. It disrupts bacterial transmembrane potential specifically, exerting bactericidal or bacteriostatic effects on pathogenic bacteria such as Clostridium difficile and Staphylococcus aureus in a non-bacteriolytic manner, and rapidly eliminates vegetative cells and spores of Clostridium difficile. It is resistant to enzymatic degradation, has iron chelating properties, and is hardly absorbed by colonic epithelial cells. In addition to effectively eliminating Staphylococcus biofilms and inhibiting the proliferation of drug-resistant bacteria, Reutericyclin regulates intestinal flora structure and improves body energy metabolism, thereby alleviating abnormal weight gain induced by risperidone medication. Currently, Reutericyclin has been widely used in basic research on Clostridium difficile infection, drug-induced weight gain and superficial skin infection caused by Staphylococcus.